Case Studies: toxin

The development of sensitive methods to quantify specfic antibodies directed against Clostridium difficile toxins and their use to provide improved immunotherapeutic products (Presentation)

Company partner:

Academic institution:

Academic discipline:

Over the past decade the ‘superbug’, Clostridium difficile, has become the most common hospital acquired infection in the developed world. Epidemic strains have emerged which exhibit enhanced virulence factors including multidrug resistance, increased capacity to form highly resistant spores and produce significantly more toxins A and B than conventional strains. This project with MicroPharm, a small bio-pharmaceutical company based in West Wales, looks at recombinant fragments based on C. difficile toxins A and B that have been used to raise antibodies in sheep.

Read more »